Clitocine, an adenosine nucleoside analog isolated from mushroom, is a potent and efficacious readthrough agent. Clitocine acts as a suppressor of nonsense mutations and can induce the production of p53 protein in cells harboring p53 nonsense-mutated alleles. Clitocine can induce apoptosis in multidrug-resistant human cancer cells by targeting Mcl-1. Anticancer activity.
In Vitro
Clitocine incorporation into mRNA is required for premature stop codon readthrough activity, and the presence of clitocine at the third position of a premature stop codon is sufficient to promote robust readthrough. Clitocine (0-0.8 μM; 24 hours) enhances TRAIL-lethality in in LS411N and SW620 cells. Clitocine (0.2μM; 36 hours) significantly potentiates TRAIL-mediated apoptosis. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Citocine (0.3-3 mg/kg; s.c.; five times per week)-induced p53 inhibits CAOV-33 p53-UAA136 tumor growth in a xenograft model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: nu/nu mice (CAOV-3p53-UAA136 xenograft tumors) Dosage: 0.3, 3 mg/kg (or 20 mg/kg once per week) Administration: S.c.; five times per week Result: CAOV-33 p53-UAA136 tumor growth was inhibited.